Dr Carl Firth is Founder and Chief Executive Officer of ASLAN Pharmaceuticals. Under Carl’s leadership, ASLAN has become Singapore’s first publicly listed biotech, completing an initial public offering in June 2017 with a listing on the Taipei Exchange. Previously, Carl was Head of Asia Healthcare at Bank of America Merrill Lynch, supporting public and private financing of healthcare companies across the region and advising on M&A transactions. Prior to joining the banking industry, Carl worked for AstraZeneca for 10 years in various commercial and R&D roles, including Regional Business Development Director, Asia Pacific, and Director of New Product Development, China. Carl was chosen as one of SCRIP’s top 10 pharmaceutical leaders alongside notable industry veterans such as Ken Frazier, CEO of Merck, and Andrew Witty, CEO of GlaxoSmithKline. Carl holds a PhD from Cambridge University in Molecular Biology (Trinity College), an Executive MBA from London Business School and a degree in Molecular Biology from Cambridge University. Carl is a member of Singapore’s Health and Biomedical Sciences International Advisory Council. Carl is also an Independent Director of Hong Kong listed Uni-Bio Sciences and Singapore’s Exploit Technologies, and is an Adjunct Professor at Duke-NUS Medical School.

pharmaceutical